Collectively, these findings highlight DPM1 as a clinically relevant regulator of tumor immune escape, with potential as both a predictive biomarker and therapeutic target to improve immunotherapy outcomes in cholangiocarcinoma. This evidence concerns the gene DPM1 and cholangiocarcinoma.